Related Experiment Video
Updated: Apr 27, 2026
Cholesterol Efflux Assay
Published on: March 6, 2012
Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells
R Hamm1, Y-R Chen2, Ean-Jeong Seo1
1Institute of Pharmacy and Biochemistry, Department of Pharmaceutical Biology, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany.
Background:
Resistance of cancer cells towards chemotherapeutics represents a major cause of therapy failure. The objective of our study was to evaluate cellular defense strategies in response to the novel vacuolar H(+)-ATPase inhibitor, archazolid B.
Experimental Approach:
The effects of archazolid B on T24 bladder carcinoma cells were investigated by combining "omics" technologies (transcriptomics (mRNA and miRNA) and proteomics). Free cholesterol distribution was determined by filipin staining using flow cytometry and fluorescence microscopy. Flow cytometry was performed for LDLR surface expression studies. Uptake of LDL cholesterol was visualized by confocal microscopy. SREBP activation was determined performing Western Blotting. The efficiency of archazolid B/fluvastatin combination was tested by cytotoxicity assays.
Results:
Archazolid B led to accumulation of free cholesterol within intracellular compartments and drastic disturbances in cholesterol homeostasis resulting in activation of SREBP-2 (sterol regulatory element-binding protein 2) and up-regulation of target genes including HMGCR (HMG-CoA reductase), the key enzyme of cholesterol biosynthesis. LDLR surface expression was reduced and LDL uptake was completely inhibited after 24h, indicating newly synthesized cholesterol to be the main source of cholesterol in archazolid B treated cells. By combining archazolid B with the HMGCR inhibitor fluvastatin, cholesterol was reduced and cell viability decreased by about 20% compared to archazolid B treatment alone.
Conclusions:
Our study revealed cholesterol biosynthesis as an important resistance mechanism in T24 cells after archazolid B treatment. The combination of archazolid B with statins may be an attractive strategy to potentiate archazolid B induced cell killing by affecting cholesterol biosynthesis.
Insights
Cancer cells resist chemotherapy by altering cholesterol. Archazolid B treatment disrupts cholesterol homeostasis, activating SREBP-2 and upregulating cholesterol synthesis. Combining Archazolid B with statins enhances cancer cell killing by targeting cholesterol biosynthesis.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Chemotherapeutic resistance is a major obstacle in cancer treatment.
- Understanding cellular defense mechanisms is crucial for overcoming resistance.
Purpose of the Study:
- To investigate cellular defense strategies against the vacuolar H(+)-ATPase inhibitor, archazolid B.
- To evaluate the role of cholesterol homeostasis in T24 bladder carcinoma cell resistance to archazolid B.
Main Methods:
- Utilized transcriptomics, proteomics, and flow cytometry to analyze cellular responses.
- Assessed free cholesterol distribution, LDLR surface expression, and SREBP activation.
- Investigated the efficacy of combining archazolid B with fluvastatin, an HMGCR inhibitor.
Main Results:
- Archazolid B induced intracellular free cholesterol accumulation and disrupted cholesterol homeostasis.
- Observed activation of SREBP-2 and upregulation of cholesterol biosynthesis genes (e.g., HMGCR).
- Combination therapy with archazolid B and fluvastatin reduced cholesterol and decreased cell viability by approximately 20%.
Conclusions:
- Cholesterol biosynthesis is identified as a significant resistance mechanism in T24 cells treated with archazolid B.
- Combining archazolid B with statins presents a promising strategy to enhance cancer cell killing by targeting cholesterol biosynthesis.
